Results 211 to 220 of about 352,162 (366)

Glucose-6 Phosphate Dehydrogenase (G-6-PD) Status, Aflatoxins and Neotanal Jaundice

open access: yesNigerian Journal of Paediatrics
Summary: In the present study of G-6 PD status, aflatoxins and neonatal jaundice, involving, 78 jaundiced and control in-born babies and 124 jaundiced and control out-born infants, G-6 PD was deficient in more male jaundiced babies (in-and out-borns ...
Ahmed H   +3 more
doaj  

A Randomized, Placebo‐Controlled Trial of Hydroxychloroquine in Incomplete Lupus

open access: yesArthritis &Rheumatology, EarlyView.
Objective Patients with features of systemic lupus erythematosus (SLE) who do not fulfill classification criteria can be designated as incomplete lupus erythematosus (ILE). This condition includes individuals with a high risk of progression to SLE. Treatment of ILE may reduce symptoms, severity, and incidence of SLE.
Nancy J. Olsen   +14 more
wiley   +1 more source

A clinical algorithm to identify people with the glucose-6-phosphate dehydrogenase p.Val68Met variant at risk for diabetes undertreatment. [PDF]

open access: yesGenet Med Open
Pershad Y   +9 more
europepmc   +1 more source

Phenotypic and genotypic characterization of glucose-6-phosphate dehydrogenase deficiency in Argentina. Retrospective and descriptive study

open access: diamond, 2019
Silvia Eandi Eberle   +12 more
openalex   +1 more source

Identification of histone deacetylase inhibitor targeting type I interferon and B‐cell abnormalities in systemic lupus erythematosus

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Systemic lupus erythematosus (SLE) is characterized by increased type I interferon (IFN‐I) and autoantibody production. This study aimed to identify drugs that can inhibit both IFN‐I and autoantibody production. Methods We identified an inhibitor of IFN‐I production from a chemical library.
Takehiro Hirayama   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy